Compare Trump Media and Technology Group Corp (DJT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs TG Therapeutics Inc — how do they compare? Trump Media and Technology Group Corp trades at $8.11 (market cap $2.28B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.6× Trump Media and Technology Group Corp's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and TG Therapeutics Inc for 16 Days on average.
| DJT | TGTX | |
|---|---|---|
Market Cap | $2.28B | $8.16B |
Volume | 3,148,379 | 1,735,121 |
Sector | Media | Health |
52-Week High | $17.07 | $59.06 |
52-Week Low | $7.06 | $26.94 |
Typical Hold Time | 17 Days | 16 Days |
Enterprise Value | $2.35B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.20, down 0.24% with a bearish technical signal. The company reported $3.68M revenue for 2025 but a net loss of $712M, reflecting negative margins. Cash flow trends show heavy investing outflows partially funded by financing. Recent news highlights a proposed merger with TAE Technologies and insider selling activity.
Outlook remains challenged by persistent losses and high valuation multiples. The merger with TAE offers strategic diversification but execution risk is high. Investor sentiment is cautious amid weak fundamentals and negative profitability trends.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
